Tavares Vladimir, Hirata Mario Hiroyuki, Hirata Rosario D Crespo
Programa de Pós-Graduação em Farmácia, Area de Análises Clínicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, Av. Prof. Lineu Prestes 580, 05508-900 São Paulo, SP.
Arq Bras Endocrinol Metabol. 2007 Jun;51(4):526-33. doi: 10.1590/s0004-27302007000400005.
The peroxisome proliferators-activated receptors (PPARs) are transcription factors belonging to the family of nuclear receptors that regulate glucose homeostasis, lipid metabolism and inflammation. Three proteins, encoded by distinct genes, have been identified: PPARalpha, PPARbeta and PPARgamma, which control gene expression by binding to specific response elements (PPREs) in the promoters. Recent studies suggest that activation of PPARgamma might decrease atherosclerosis progression and increase the insulin sensitivity, might be a potential therapeutic target for the treatment of a diverse array of disorders, including type 2 diabetes and dyslipidaemia. This review highlights recent studies, which have advanced our understanding of the pivotal role that this receptor plays in metabolism, with particular reference to the molecular mechanisms and therapeutic efficacy.
过氧化物酶体增殖物激活受体(PPARs)是属于核受体家族的转录因子,可调节葡萄糖稳态、脂质代谢和炎症。已鉴定出由不同基因编码的三种蛋白质:PPARα、PPARβ和PPARγ,它们通过与启动子中的特定反应元件(PPREs)结合来控制基因表达。最近的研究表明,PPARγ的激活可能会减缓动脉粥样硬化进展并提高胰岛素敏感性,可能是治疗包括2型糖尿病和血脂异常在内的多种疾病的潜在治疗靶点。本综述重点介绍了最近的研究,这些研究加深了我们对该受体在代谢中所起关键作用的理解,特别是在分子机制和治疗效果方面。